Piper Jaffray analyst Danielle Brill keeps her Overweight rating and $74 price target on Acceleron after its discontinued Phase 1 safety trial of ACE-2494. The analyst says the program was already seen as ” high-risk due to several failures with similar approaches” and it was not included in her valuation. The analyst keeps a positive view on the stock, expecting the company’s Phase 2 myelofibrosis data to drive shares higher in the second half of 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.